Sensory information from the gastrointestinal (GI) tract is received and integrated by neurones in the nucleus of the tractus solitarius (NTS). The output of these NTS neurones then influences the discharges of the dorsal vagal motoneurones of the dorsal motor nucleus of the vagus (DMV) (Altschuler et al. 1989 (Altschuler et al. , 1991 Rogers et al. 1999) . The NTS utilizes, in the main, a tonic inhibitory GABAergic input to the DMV as well as an excitatory glutamatergic input Sykes et al. 1997) . The DMV then provides efferent outflow to the GI tract through the subdiaphragmatic vagal branches (Norgren & Smith, 1988; Berthoud et al. 1991) . The DMV preganglionic motoneurones have been shown to control both tonic excitatory cholinergic as well as inhibitory non-adrenergic, non-cholinergic (NANC) postganglionic neurones in the gut (Forster & Southam, 1993; Barnes et al. 1994; Yu, 1994; Panico et al. 1995; Takahashi & Owyang, 1995; Esplugues et al. 1996; Lawrence, 1997; Beltran et al. 1999; Krowicki et al. 1999; Zheng et al. 1999; Guo et al. 2001; Quintana et al. 2001 ).
The DMV also receives input from higher CNS centres, including the paraventricular nucleus of the hypothalamus (PVN) (Rogers et al. 1980) , and Barrington's nucleus (Valentino et al. 1995) . Corticotropin releasing factor (CRF) is one of a number of neuronal modulators released from neurones with soma in the PVN and Barrington's nucleus (Cummings et al. 1983; De Souza & Kuhar, 1986; Valentino et al. 1995) . Nerve fibres immunoreactive for CRF and CRF binding sites are observed in both the NTS and the DMV (De Souza et al. 1985; Skofitsch et al. 1985; De Souza & Kuhar, 1986; De Souza, 1987; Sakanaka et al. 1987; Herbert & Saper, 1990; Bittencourt et al. 1999) .
Various stressors such as abdominal surgery, restraint and cold have been shown to induce dramatic effects on the GI function in laboratory animals (Gue et al. 1987; Coskun et al. 1997; Martinez et al. 1997) . These effects can be mimicked by injection of CRF in the cisterna magna, lateral ventricles, DVC or PVN and induce a decrease in gastric acid secretion, gastric emptying, small bowel transit In vitro and in vivo analysis of the effects of corticotropin releasing factor on rat dorsal vagal complex Mark W. Lewis *, Gerlinda E. Hermann †, Richard C. Rogers † and R. Alberto Travagli * ‡ Departments of * Gastroenterology and ‡ Physiology, University of Michigan, Ann Arbor, MI and † Pennington Biomedical Research Center, Baton Rouge, LA, USA In vivo and in vitro electrophysiological experiments were performed on the rat dorsal vagal complex (DVC, i.e. nucleus of the tractus solitarius, NTS, and dorsal motor nucleus of the vagus, DMV) to examine the effects of corticotropin releasing hormone (CRF) on the central components of the vago-vagal reflex control of gastric function. When applied to gastrointestinal projecting DMV neurones, CRF (10-300 nM) induced a concentration-dependent membrane depolarization, an increase in action potential firing rate and decrease in amplitude of the action potential afterhyperpolarization (P < 0.05). Pretreatment with the non-selective CRF antagonist, astressin (0.5-1 mM) or the selective CRF 2 receptor antagonist, astressin 2B (500 nM) attenuated the CRFinduced increase in firing rate but did not alter basal discharge rate. CRF (30-300 nM) increased the amplitude of excitatory postsynaptic currents (EPSCs) evoked by stimulation of the NTS (P < 0.05). An alteration in the paired pulse ratio indicated the EPSC's increase occurred due to actions at presynaptic sites. In the in vivo anaesthetized rat preparation, bilateral microinjections (20 fmol in 20 nl for each site) of CRF in the DVC decreased gastric motility in rats pretreated with the muscarinic agonist, bethanecol (P < 0.05). The effects of CRF were abolished by systemic administration of the NOS inhibitor, L-NAME, or by bilateral vagotomy. We concluded that CRF had both a direct and an indirect excitatory effect on DMV neurones via activation of CRF 2 receptors and the decrease in gastric motility observed following microinjection of CRF in the DVC is due to the activation of an inhibitory non-adrenergic non-cholinergic input to the gastrointestinal tract. (Received 19 February 2002; accepted after revision 29 May 2002) time and an increased large bowel transit time (Tache et al. 1983 (Tache et al. , 1987 Garrick et al. 1988; Heymann-Monnikes et al. 1991; Monnikes et al. 1992; Smedh et al. 1995; Coskun et al. 1997; Martinez et al. 1997 Martinez et al. , 1998 . Furthermore, the stress-related and the CRF-induced GI effects are blocked by pretreatment with CRF antagonists (Lenz et al. 1988; Coskun et al. 1997; Martinez et al. 1997) .
Recent in vivo studies conducted by Tache's group using systemic administration of CRF and its analogues have suggested that the gastric inhibitory effects of CRF might be mediated by activation of CRF 2 receptors (Martinez et al. 1998) . Despite the tremendous volume of descriptive work, which supports the involvement of CRF in stressinduced alterations in GI function, little is known about the cellular mechanisms responsible for these actions of CRF in the DVC.
Based on previous studies showing that in different neuronal populations the prevalent postsynaptic effect of CRF is excitatory (Eberly et al. 1983; Siggins et al. 1985; Yamashita et al. 1991; Hille, 1992; Curtis et al. 1997; Page & Abercrombie, 1999; Haug & Storm, 2000) , and that the NTS contains a more dense CRF-immunoreactivity (IR) and urocortin-IR fibre innervation than the DMV (Herbert & Saper, 1990; Bittencourt et al. 1999) , we performed a series of experiments to test the hypotheses that: (1) the effects of CRF on identified gastric-projecting DMV neurones were mediated by both a direct membrane depolarization and by an increase in excitatory synaptic transmission between the NTS and the DMV, and (2) the inhibition of gastric motility induced by microinjection of CRF in the DVC was mediated by activation of the NANC pathway rather than withdrawal of cholinergic tone.
METHODS
Animal care and experimental procedures were performed with the approval of the Animal Care and Utilization Committees of the University of Michigan (in vitro studies) and Ohio State University (in vitro studies).
In vitro brain slice studies Slice preparation. Sprague-Dawley rats were purchased from Charles River Laboratories, Inc. (Wilmington, MA, USA). GIprojecting DMV neurones were labelled as described previously (Browning et al. 1999) . Briefly, 11-day-old rat pups of either sex were anaesthetized deeply (indicated by abolition of the foot pinch withdrawal reflex) by inhalation of a 6 % solution of halothane in air (400-600 ml min _1 ) before an abdominal laparotomy was performed. During surgery, anaesthesia was maintained by placing the head of the rat in a custom-made anaesthetic chamber through which the halothane-air mixture was perfused. Crystals of the retrograde tracer DiI (1,1‚-dioctadecyl-3,3,3‚‚3‚-tetramethylindocarbocyanine perchlorate (DiIC 18 (3); DiI; Molecular Probes, Eugene, OR, USA) were applied to the serosal surface of the gastric fundus, corpus or antrum/pylorus areas or duodenum and the application site was embedded in a fast-hardening epoxy resin that was allowed to dry for several minutes before the entire surgical area was washed with warm saline (Browning et al. 1999 ).
The wound was closed with 5/0 suture and the animal allowed to recover for 10-15 days under the monitoring of veterinary staff.
The brainstems were removed as described previously (Travagli et al. 1991; Browning et al. 1999) . Briefly, the rats were placed in an anaesthetic chamber and anaesthetized with 6% halothane and killed by severing the major blood vessels in the chest. The brainstem was removed and placed in oxygenated Krebs solution at 4°C (see Solution composition). The site of DiI labelling in the stomach (i.e. fundus, corpus or antrum/pylorus) or in the intestine was confirmed by visual inspection of the organ. We sliced the brainstems only from those animals in which the glue covering the site of DiI application was still in place. Using a vibratome, six to eight coronal sections (200 mm thick) containing the DVC were cut and stored in oxygenated Krebs solution at 30°C for at least 1 h prior to use. A single slice was transferred to a custom-made perfusion chamber (volume 500 ml) and kept in place using a nylon mesh. The chamber was maintained at 35 ± 1°C by perfusion with warmed, oxygenated Krebs solution at a rate of 2.5-3.0 ml min _1 .
Prior to electrophysiological recording, DiI-labelled GI-projecting DMV neurones were identified using a Nikon E600-FS microscope equipped with epifluorescent filters suitable for visualizing DiI. We exposed the DVC to fluorescent light using TRITC filters to identify the fluorescent neurone(s) and, once the identity of a labelled neurone was confirmed, we switched the illumination to brightfield. Whole-cell recordings were made under brightfield illumination.
Electrophysiological recording. Whole-cell recordings were made with patch pipettes (3-8 MV resistance) filled with a potassium gluconate solution using an Axoclamp-2B single electrode voltage clamp amplifier (Axon Instruments, Union City, CA, USA). Recordings were made only from neurones unequivocally labelled with DiI. Data were sampled every 100 ms and filtered at 2 kHz, digitized via a Digidata 1200C interface (Axon Instruments) acquired, stored and analysed on an IBM PC utilizing pCLAMP 8 software (Axon Instruments). Recordings were accepted only if the series resistance was < 15 MV. In addition, the action potential evoked following injection of depolarizing current had to have an amplitude of at least 60 mV and the membrane potential had to return to the baseline value following the action potential afterhyperpolarization.
Electrical stimulation. Bipolar tungsten electrodes were used to electrically stimulate the NTS. Paired stimuli (0.1-1.0 ms, 10-500 mA; 15-100 ms interval) were applied every 20 s to evoke submaximal excitatory (EPSCs) postsynaptic currents . A minimum of six control EPSCs were obtained and averaged prior to each drug application. Drugs were applied to the bath via a series of manually operated valves.
In vivo rat studies Animal preparation. Experiments were performed on rats (n = 15) weighing 250-400 g. Animals were anaesthetized with an intraperitoneal injection of thiobutabarbital (Inactin; 100 mg kg _1 ). An adequate depth of anaesthesia was assessed by the absence of the foot pinch withdrawal reflex. Body temperature was monitored by a rectal thermometer and maintained at 37 ± 1°C with a heating pad.
Surgery. Rats were intubated to maintain an open airway. A jugular cannula was placed for the administration of intravenous drugs. In animals that underwent cervical vagotomy, loose 5/0 silk ligatures were tied around the vagus nerves and the trailing ends passed through a 3 cm length of PE 240 tubing. Later, the ligatures were pulled out through the tube to cut the nerve.
An abdominal laparotomy was performed and a strain gauge (RB Products, Madison, WI, USA) was sewn onto the surface of the gastric corpus as described in previous reports . The laparotomy was closed with the strain gauge leads exiting the abdomen. Strain gauge gastric motility data were digitized and stored using a DataPac2000 PC-based waveform analysis system (Run Technologies, Laguna Hills, CA, USA). Motility data were saved for analysis at a later time.
The animals were then positioned in a stereotaxic apparatus (David Kopf, Tujunga, CA, USA). A partial dorsal craniotomy was performed to expose the fourth ventricle. The cerebellum was retracted slightly while using a 26-gauge needle to cut the subarachnoid covering. Calamus scriptorius (CS) was viewed from the dorsal aspect and used as a point of reference (see below). A 1 h recovery period preceded experimental manipulations during which strain gauge activity was monitored continuously, digitized and stored.
Experimental procedure. Pipettes (tip diameter of between 10-30 mm) were filled with either CRF in phosphate-buffered saline (PBS), or PBS alone, and were placed in a hydraulic microdrive carrier. The pipette was directed toward the CS to establish a zero reference for subsequent placement of the pipette in the DVC. The pipette was first positioned at a point 0.3 mm anterior and 0.3 mm left from CS on the brainstem surface. The pipette was then advanced to a point 0.4 mm ventral to the brainstem surface. This location corresponds to the DVC, an area well known to contain the cell bodies of the main brainstem areas involved in the gastric vago-vagal reflex control circuitry (McCann & Rogers, 1992; Rogers et al. 1999) . Baseline gastric motility was increased by systemic (I.V.) administration of the muscarinic agonist, bethanecol (50 mg kg _1 bolus followed by continuous I.V. infusion with 20 mg kg _1 h _1 for 20 min). Two minutes after I.V. administration of bethanecol, CRF (20 nl w 10 _6 M CRF = 20 fmol; n = 5) or PBS (20 nl; n = 4) were micropressure injected into the DVC under direct microscopic control . The procedure was then repeated on the right side. The bilateral DVC injection procedure took less than 1 min to complete.
In three additional cases, the nitric oxide synthase inhibitor, N G -nitro-L-arginine methyl ester (L-NAME; 10 mg kg _1 bolus I.V. injection) (Takahashi & Owyang, 1995 was injected 20 min prior to bethanecol administration. CRF was injected into the DVC as described. In three more cases, rats received bilateral cervical vagotomy 20 min prior to bethanecol administration. Although these animals developed apneustic breathing after vagal section, all survived without auxiliary ventilation.
Histological verification.
At the end of the experiment all rats were killed with an I.V. dose of lidocaine (0.3 ml w 2 %). Brains were removed and fixed in a mixture of 4 % paraformaldehyde and 20 % sucrose in PBS for at least 48 h. The brains were cut into 40 mm thick coronal sections and stained with Nuclear Fast Red (Vector Labs; Berlingame, CA, USA). Location of nuclear groups was studied in relation to microinjection sites using the atlas of Paxinos & Watson (1986) .
Data analysis
In vitro experiments. Electrophysiological data were analysed using Clampex (pCLAMP 8 software package, Axon Instruments). To assess the effects of drugs, each neurone served as its own control (i.e. the results obtained after administration of a drug were compared with those before administration using Student's paired t test).
Data were obtained from spontaneously active DMV neurones or from DMV neurones hyperpolarized to _65 mV by current injection. When tested on spontaneously active DMV neurones, the CRF-induced increase in firing rate was assessed as the number of action potentials counted during the 20 s preceding the administration of the drug and during the 20 s of maximal firing rate increase following drug superfusion. When tested on silent neurones, the response to CRF was assessed as a change in membrane potential. The amplitude of the evoked excitatory postsynaptic currents (EPSCs) was obtained from the average of three to six EPSCs in control and following superfusion with CRF or its antagonists.
All concentration-response curves were constructed only from neurones in which at least three concentrations (at 5-15 min intervals and always given in random order) were tested. DMV neurones were classified as CRF responders if a 1 min-long perfusion with 100 nM CRF resulted in either a minimum 15 % change in the frequency of action potential firing, a variation of at least 1.25 mV in membrane potential, or at least 10 % change in the EPSC amplitude all of which returned to baseline values upon washout of CRF.
Results are expressed as means ± S.E.M. Significance was set at P < 0.05.
In vivo experiments. Motility data were analysed using DataPac2000. Motility records were divided into three epochs; 2 min before bethanecol (basal period), 2 min after I.V. bethanecol (maximum motility) and 2 min after completion of the DVC injection. The area under the motility curves was determined for each 2 min epoch and expressed in volts per second. Data from all three epochs were subjected to an analysis of variance followed by Tukey's multiple comparison post hoc test.
Solution composition
Intracellular electrode solution was composed of (mM): 128 potassium gluconate, 10 KCl, 0.3 CaCl 2 , 1 MgCl 2 , 1 Hepes, 1 EGTA, 2 ATP, 0.25 GTP, adjusted to pH 7.35 with KOH. Krebs solution was composed of (mM): 126 NaCl, 25 NaHCO 3 , 2.5 KCl, 1.2 MgCl 2 , 2.4 CaCl 2 , 1.2 NaH 2 PO 4 and 11 dextrose, maintained at pH 7.4 by bubbling with 95 % O 2 -5 % CO 2 . Phosphate-buffered saline (PBS) was composed of (mM): 124 NaCl, 26 NaHCO 3 , 2 KH 2 PO 4 adjusted to 304 mosmol kg _1 and pH 7.4. A histological marker (Pontamine Blue, 5 mg ml _1 ) for locating injection sites was added to PBS.
Drugs and chemicals
All drugs were purchased from Sigma Chemical Co., St Louis, MO, USA except for astressin 2B which was a generous gift from Professor J. Rivier (Salk Institute, San Diego, CA, USA).
RESULTS

In vitro studies
Whole-cell patch clamp studies were conducted on 203 neurones; 172 identified gastric-projecting (36 fundus-, 60 corpus-and 76 antrum/pylorus-projecting neurones) and 31 duodenal-projecting neurones. Results did not differ J. Physiol. 543.1 Figure 1 . CRF induced a concentration-dependent increase in discharge rate and membrane depolarization A, representative traces from a gastric-projecting DMV neurone illustrating the concentration-dependent increase in discharge rate induced by superfusion of nanomolar concentrations of CRF. Neurones were spontaneously active and were monitored for stability for a minimum of 2 min before the superfusion of CRF. The horizontal line above the traces indicates perfusion of CRF for a time sufficient to reach the response plateau. In the depicted example the firing rate was 0.95 Hz in control, 1.35, 1.7 and 2.45 Hz in 10, 30 and 100 nM CRF, respectively. The increase in discharge rate did not desensitize even at high concentrations. The parallel oblique lines indicate a 3.5 min period. A recovery period of at least 5 min was allowed between successive applications, during which the firing rate returned to baseline values. B, concentration-response curve for the CRF-induced increase in discharge rate (0; n = 7) and membrane depolarization (1; n = 8). Each neurone was tested with at least three different concentrations of CRF. *P < 0.05 vs. baseline. among the various projection groups and were thus pooled.
Effects of CRF on DMV neurones. Sixty-four percent of neurones (i.e. 103 of 160) responded to 100 nM CRF with either a change in discharge rate or membrane depolarization at or above the minimum criteria. Sixty cells (49 gastric-and 11 intestinal-projecting neurones) showed an increase in discharge rate from 0.9 ± 0.07 Hz in control to 1.7 ± 0.12 Hz in 100 nM CRF (P < 0.05), two cells showed a decrease in discharge rate (one cell decreased from 0.8 to 0 Hz in CRF and the second cell decreased from 2.0 to 1.28 Hz in CRF; both cells recovered upon washout, this type of response was not investigated further). Additionally, CRF 100 nM depolarized 41 cells (35 gastric-and 6 intestinalprojecting neurones) by 4.0 ± 0.23 mV (P < 0.05), while no cells were hyperpolarized and 57 cells were unresponsive. Concentration-response curves were constructed from cells in which at least three concentrations of CRF (10-300 nM) were tested (Fig. 1) .
The response to CRF did not show tachyphylaxis. In fact, two 1 min superfusions of 100 nM CRF within 5 min gave similar results. In detail, the first superfusion of CRF depolarized the membrane by 3.2 ± 0.55 mV (P < 0.05 vs.control; n = 7) or increased the frequency of action potential firing from 0.97 ± 0.09 to 2.1 ± 0.3 Hz (i.e. 122 ± 32.7 %; P < 0.05; n = 6) while the second superfusion of CRF depolarized the membrane by 3.2 ± 0.49 mV or increased the firing rate by 156 ± 63.7 % (P < 0.05 vs. control; P > 0.05 vs. first application; Fig. 2 ).
To ascertain whether the CRF-induced depolarization was due to a direct effect of CRF on the DMV cell, we compared the amplitude of the CRF-induced membrane depolarization in the absence and presence of the synaptic transmission blocker, tetrodotoxin (TTX; 0.3 mM). In ten neurones, CRF induced a 3.3 ± 0.44 mV depolarization that recovered to baseline upon washout. Following 10 min of perfusion with TTX, reapplication of CRF in the presence of TTX induced a 3.1 ± 0.63 mV depolarization (i.e. 92 ± 14 % of control, P > 0.05 vs. CRF alone; Fig. 2) .
In five cells, CRF increased the discharge rate from 1.1 ± 0.23 to 2.5 ± 0.67 Hz (i.e. 182 ± 67 % of control; P < 0.05). Following washout of CRF and 10 min pretreatment with the non-selective CRF antagonist, astressin (0.5 -1 mM), the baseline firing rate did not change, but the CRF- Figure 3 . The CRF-induced increase in discharge rate was attenuated by the non-selective CRF antagonist, astressin, and the selective CRF 2 antagonist, astressin 2B A, upper trace, representative current-clamp trace from a gastric-projecting DMV neurone illustrating the CRF-induced increase in discharge rate (from 2.1 to 3.9 Hz in control and following perfusion with 100 nM CRF, respectively). Middle trace, after a 5 min washout of CRF, the CRF antagonist, astressin (1 mM), was perfused for at least 7 min. Astressin had no effect on the basal firing rate (1.8 Hz before and during astressin perfusion). Lower trace, in the presence of astressin (1 mM), perfusion with CRF did not increase significantly the firing rate (from 1.8 to 1.9 Hz in astressin and in astressin + CRF, respectively). The astressin-mediated blockade of the CRF response was reversible (data not shown). Double parallel oblique lines indicate a 3.5 min period. B, summary showing the effects of astressin and astressin 2B on the excitatory effect of CRF. Bar graph shows the mean basal discharge rate and the CRF effect on the discharge rate before and in the presence of astressin (n = 5) or astressin 2B (n = 4) (*P < 0.05 vs. control).
induced increase in action potential firing rate was attenuated from 182 ± 67 % in control to 14 ± 9 % in astressin (P < 0.05 vs. control; Fig. 3 ). In a further four cells, CRF increased the discharge rate from 1.1 ± 0.28 to 1.9 ± 0.37 Hz (i.e. 75 ± 13 % of control; P < 0.05). Following washout of CRF and 10 min superfusion with the selective CRF 2 antagonist (Chen et al. 2001 ) astressin 2B (500 nM), the baseline firing rate did not change, but the CRF-induced increase in discharge rate was reduced from 75 ± 13 % in control to 16 ± 16 % in astressin 2B (P < 0.05 vs. control; Fig. 3B ).
The effect of CRF on the shape of the action potential was tested in six CRF-responsive neurones. The cells were hyperpolarized to _60 mV before being injected with a 10 ms-long pulse of DC sufficient to evoke a single action potential at its offset. The amplitude of the afterhyperpolarization (AHP) in control conditions was 15.3 ± 0.72 mV. Following CRF (100 nM) perfusion, current was injected to return the membrane potential to baseline values and a 10 ms-long pulse of DC was injected. In the J. Physiol. 543.1
Figure 4. CRF decreased the amplitude of the afterhyperpolarization (AHP)
To evoke single action potentials, neurones were maintained at _60 mV by constant current injection before passing a short (10 ms) depolarizing current pulse of sufficient intensity to evoke an action potential at the offset of the pulse. A, current-clamp trace shows a single action potential before and after superfusion with 100 nM CRF. B, summary of data illustrating the CRF-induced decrease in AHP relative to the control AHP (n = 6). *P < 0.05. presence of CRF, the amplitude of the action potential AHP was reduced to 14 ± 0.7 mV (P < 0.05 vs. control; Fig. 4 ).
The DMV membrane input resistance (calculated as the average of 20-40 electrotonic potentials evoked by injection of DC (50 ms on-950 ms off) sufficient to hyperpolarize the membrane by 5-7 mV) was measured in 15 neurones. Superfusion with CRF (100 nM) induced a 3.3 ± 0.4 mV depolarization; negative DC was then injected to restore the membrane potential to the value before CRF application. The input resistance was 461 ± 46 MV in control and 449 ± 57 MV in presence of CRF (P > 0.05).
In seven other neurones, the input resistance was measured in the presence of TTX. In these neurones, superfusion with CRF (100 nM) induced a 2.75 ± 0.32 mV depolarization; negative DC was then injected to restore the membrane potential to the value before CRF application. In four of the seven neurones, the input resistance in presence of CRF increased from 301 ± 84 to 337 ± 93 MV (P < 0.05) while in three other neurones no variations in the input resistance were observed.
Effects of CRF on EPSCs. EPSCs were evoked in 43 neurones by electrical stimulation of the NTS. In 16 of 43 (37 %) neurones, CRF (100 nM) increased the evoked EPSC amplitude from 218 ± 18.3 to 266 ± 21.7 pA (i.e. an increase of 22 ± 2.2 %; P < 0.05; Fig. 5 ). The paired pulse ratio is the ratio of the amplitude of the second evoked EPSC to the first evoked EPSC (C2/C1) and it is used as an indication of the site of drug action; a change in the ratio is taken as indication of a presynaptic site of action (Travagli & Williams, 1996; ). In the aforementioned 16 cells, the paired pulse ratio was 0.56 ± 0.05 in control and 0.47 ± 0.06 in CRF thus indicating that CRF acts at presynaptic sites (P < 0.05 vs. control; Fig. 5 ). Concentration-response curves were constructed from cells in which all three concentrations of CRF (30-300 nM) were tested (n = 5; Fig. 5 ). In detail, Figure 7. The CRF-induced decrease in gastric motility is abolished by the nitric oxide synthase inhibitor, L-NAME and vagotomy A, representative raw motility traces showing that the bethanecol-induced increase in gastric motility was decreased by the microinjection of CRF in the DVC. B, vagotomy eliminated the CRF-induced decrease in gastric motility. C, intravenous L-NAME also eliminated the CRF-induced decrease in gastric motility.
30 nM CRF increased the mean EPSC amplitude from 241 ± 29.3 to 250 ± 29.1 pA (i.e. 4 ± 5.2 % over control), while 100 nM CRF increased the mean EPSC amplitude from 260 ± 40.0 to 305 ± 42.8 pA (i.e. 18 ± 2.6 % over control) and 300 nM CRF increased the mean EPSC amplitude from 222 ± 17.8 to 283 ± 38.4 pA (i.e. 27 ± 13.7 % over control).
In vivo studies
Effects of CRF on gastric motility. Vagally mediated GI functions are controlled by two separate pathways: a cholinergic-excitatory muscarinic pathway and a NANC inhibitory pathway (Abrahamsson, 1986; Boeckxstaens et al. 1991; Desai et al. 1991; Lefebvre et al. 1992; Meulemans et al. 1995; Takahashi & Owyang, 1995; Hozer-Petsche & Moser, 1996; Mashimo et al. 1996; Kim et al. 1999) . A vagally mediated decrease in gastric motility could then be obtained either by withdrawal of cholinergic tone or by activation of NANC pathways.
Experiments were performed on 15 anaesthetized rats in which baseline gastric motility was increased by systemic administration of the muscarinic agonist, bethanecol (50 mg kg _1 bolus followed by continuous I.V. bethanecol infusion 20 mg kg _1 h _1 for 20 min). Two minutes after administration of bethanecol either CRF (n = 5) or PBS (n = 4) was delivered bilaterally to the DVC. If, despite the supramaximal cholinergic stimulation via bethanecol, CRF reduced gastric motility, we could then infer that the effects of CRF are not mediated by withdrawal of cholinergic tone to the stomach but rather by activation of NANC pathways.
In the basal state, gastric motility was 11 ± 3.2 V s, following intravenous injection of bethanecol gastric motility significantly increased within 30 s of perfusion to reach a plateau value of 343 ± 31.6 V s (n = 15; P < 0.05; Fig. 7 ).
In four rats basal motility was 11 ± 9 V s, following bethanecol infusion, motility increased to 417 ± 34 V s and following bilateral microinjection of PBS in the DVC motility was unchanged (394 ± 87.5 V s; n = 4; P > 0.05). Compared with the effects of 20 nl of PBS injected into the DVC, bilateral microinjection of CRF in the DVC produced a very large reduction in gastric motility (i.e. from 17 ± 8.2 V s in control, to 373 ± 62.5 V s following bethanecol to 63 ± 34.3 V s in CRF; n = 5; P < 0.05; Figs 7 and 8). The measures of gastric motility following CRF injections into the DVC were not statistically different from the basal condition (Fig. 8) . In two animals, we injected CRF outside the borders of the DMV; no alteration in gastric motility or tone was observed (data not shown). Intravenous administration of L-NAME or bilateral vagotomy antagonized the inhibition of gastric motility induced by CRF microinjections in the DVC (Figs 7 and 8) . In either cases (L-NAME and vagotomy), gastric motility remained at levels not significantly different from the maximal levels observed after bethanecol, but were significantly greater than the levels observed after CRF alone. In detail, bethanecol infusion in the presence of L-NAME increased the motility from 6 ± 4.4 to 250 ± 64.4 V s, bilateral microinjection of CRF in the DVC did not significantly affect motility (i.e. 328.7 ± 107 V s; n = 3; P > 0.05). Similarly, bethanecol infusion following J. Physiol. 543.1 Figure 8 . Summary of the CRF-induced inhibition of the bethanecol-induced increase in gastric motility Two minutes after I.V. bethanecol, either CRF or PBS (control) was bilaterally microinjected in the DVC. From left to right: the first group of columns compares the bethanecol-stimulated gastric motility to control and following the microinjection of PBS in the DVC; the second group of columns compares the bethanecolstimulated gastric motility to control and following the microinjection of CRF in the DVC; the third group of columns compares the effect of the NOS inhibitor, L-NAME, on the bethanecol-stimulated gastric motility vs. control and following the microinjection of CRF in the DVC; the fourth group of columns compares the effect of bilateral vagotomy on the bethanecol stimulated gastric motility vs. control and following the microinjection of CRF in the DVC. *P < 0.05 vs. control, **P < 0.05 vs. bethanecol. vagotomy increased the motility from 6 ± 3.2 to 286 ± 71 V s, bilateral microinjection of CRF in the DVC did not significantly affect motility (i.e. 280 ± 80.3 V s; n = 3; P > 0.05). The analysis of variance showed the treatment effect across all groups to be statistically significant; P < 0.05).
DISCUSSION
In this study we have shown that (1) in the in vitro rat brainstem slice preparation, perfusion with CRF induced a concentration-dependent excitation of vagal neurones. The CRF-mediated excitation was due to a direct depolarization of the DMV membrane as well as to an increase of the excitatory neurotransmission between the NTS and DMV neurones; and (2) in the in vivo anaesthetized rat preparation, bilateral microinjection of CRF in the DVC produced a vagally mediated inhibition of gastric motility via activation of inhibitory NANC neurones. Our data led us to conclude that the gastric inhibitory actions of CRF in the DVC result from the activation of CRF 2 receptors, which increase activity in NANC inhibitory pathways. The following experimental evidence supports our conclusions.
CRF excites GI-projecting DMV neurones
Superfusion with CRF induced a concentration-dependent excitation of identified gastric-and duodenal-projecting DMV neurones via two separate mechanisms. The first mechanism was a direct depolarization of DMV neurones, most likely determined by a reduction in the amplitude of the AHP. The CRF-induced depolarization was mediated by activation of CRF 2 receptors because both the nonselective CRF antagonist, astressin, as well as the selective CRF 2 antagonist, astressin 2B, significantly attenuated the CRF-induced excitation of the DMV membrane. The second mechanism was via an increase in the amplitude of the EPSCs evoked by electrical stimulation of the NTS.
Our data on the excitatory effects of CRF are in line with current literature reporting that in the majority of the CNS neurones CRF has a depolarizing effect, most likely due to a decrease in the amplitude of the AHP (Eberly et al. 1983; Siggins et al. 1985; Yamashita et al. 1991; Hille, 1992; Fox & Gruol, 1993; Curtis et al. 1997; Page & Abercrombie, 1999; Haug & Storm, 2000) .
Our pharmacological data confirmed and extended the suggestion put forward by Tache's group which suggested that the centrally mediated CRF inhibition of gastric emptying was likely mediated via the CRF 2 receptor (Martinez et al. 1998) .
CRF in the DVC significantly inhibited gastric motility
Vagally mediated GI functions are controlled by two separate pathways: a cholinergic-muscarinic pathway, whose activation induces an increase of GI functions, and a NANC pathway, whose activation induces a decrease in GI functions mainly via release of nitric oxide (NO) on to gastric smooth muscle (Abrahamsson, 1986; Boeckxstaens et al. 1991; Desai et al. 1991; Lefebvre et al. 1992; Meulemans et al. 1995; Takahashi & Owyang, 1995; Hozer-Petsche & Moser, 1996; Mashimo et al. 1996; Kim et al. 1999) . A vagally mediated decrease in gastric motility could then be obtained either by withdrawal of the excitatory cholinergic tone or by activation of inhibitory NANC pathways.
Results from our in vitro study showed that the effects of CRF within the DVC were exclusively excitatory while our in vivo studies, as well as the studies already available in literature (Tache et al. 1983 (Tache et al. , 1987 Garrick et al. 1988; Heymann-Monnikes et al. 1991; Monnikes et al. 1992; Smedh et al. 1995; Coskun et al. 1997; Martinez et al. 1997 Martinez et al. , 1998 , show that the effects of CRF microinjection in the DVC were exclusively gastroinhibitory. The in vitro and in vivo results obtained in the present study would then suggest that the gastroinhibitory effects of CRF were due to activation of the NANC pathway, possibly, via release of NO in the gastric smooth muscle. We conducted the following experiments to test the hypothesis that NANC pathways, but not cholinergic pathways, were involved in the gastric relaxation induced by CRF. Our experimental design was based on the premise that, to study the inhibitory effects of CRF on gastric motility, the cholinergic activity of the stomach would have to be substantially increased. If CRF were to antagonize the muscarinic-cholinergic activity of the stomach we would have not been able to ascertain it with the use of systemic injection of the muscarinic antagonist atropine, because gastric motility would be decreased to a level such that it would not be possible to detect a further decrease in motility carried by the activation of the inhibitory NANC pathway. To circumvent this problem, we increased gastric motility by systemic injection of the muscarinic agonist, bethanecol at a supramaximal dose. If the microinjection of CRF in the DVC failed to decrease gastric motility in the bethanecoltreated rats, then we would surmise that the actions of CRF were mediated via muscarinic-cholinergic receptors. If instead, CRF were to decrease gastric motility in the bethanecol-treated rats, this would suggest that the CRFinduced decrease in gastric motility was mediated by a mechanism other than the cholinergic-muscarinic pathway, perhaps the NANC pathway. Indeed, our in vivo results showed that despite a supramaximal activation of muscarinic cholinergic receptors, microinjections of CRF in the DVC still induced a decrease in gastric motility, thus arguing in favour of an NANC pathway, but against the withdrawal of a cholinergic pathway as the gastric inhibitory mechanism.
Much of the vagal NANC inhibitory effect on the stomach is mediated by the release of nitric oxide onto gastric smooth muscle (Abrahamsson, 1986; Boeckxstaens et al. CRF in rat dorsal vagal complex 1991; Desai et al. 1991; Lefebvre et al. 1992; Meulemans et al. 1995; Takahashi & Owyang, 1997; Kim et al. 1999 ). Therefore, we tested the hypothesis that the nitric oxide synthase inhibitor N G -nitro-L-arginine methyl ester (L-NAME) would block the effects of CRF in the DVC despite the bethanecol-induced increase in gastric motility.
Indeed, bilateral microinjections of CRF in the DVC significantly inhibited gastric motility in rats pretreated with bethanecol, and the effects of CRF on GI motility were abolished by systemic injection of L-NAME (or bilateral vagotomy), thus suggesting that excitation of a vagal pathway that uses NO as neurotransmitter mediated the effects of CRF. Our results are in contrast to a recent report that, by using extracellular recordings from isolated 'efferent' vagal fibres, suggested that the gastric relaxation induced by intracisternal administration of CRF was determined by a decrease in vagal firing (Kosoyan et al. 1999) . This discrepancy may be due to the fact that, in his work, Kosoyan recorded from intact vagal preparations, which include fibres projecting to other GI regions (Berthoud et al. 1991) , making his analysis difficult to interpret.
Physiological significance
Numerous studies in rats have shown that injection of CRF in the cisterna magna, lateral ventricles, DVC and PVN induce a decrease in gastric acid secretion, gastric emptying, small bowel transit and an increased large bowel transit (Tache et al. 1983 (Tache et al. , 1987 Garrick et al. 1988; HeymannMonnikes et al. 1991; Monnikes et al. 1992; Smedh et al. 1995; Coskun et al. 1997; Martinez et al. 1997 Martinez et al. , 1998 . Such varied GI effects are similar to those observed in response to stress. Indeed, the effects that are observed in response to stress are mimicked by the I.C. injection of CRF and both the stress-related and the CRF-induced GI-effects are blocked by the various CRF antagonists such as a-helical CRF 9-41 , d-Phen CRF 12-41 and astressin (Lenz et al. 1988; Coskun et al. 1997; Martinez et al. 1997) . In the absence of exogenous CRF or stress, the CRF antagonists do not affect gastric activity, suggesting that CRF does not modulate basal digestive activity (Lenz et al. 1988; Smedh et al. 1995; Martinez et al. 1997 Martinez et al. , 1998 . Taken together, the evidence suggests that, in the time of stress, CRF acts as a central neurotransmitter in the DMV to control gastric function.
In summary, CRF acts within the DVC to decrease gastric motility and intragastric pressure. The effect of CRF in the DVC is mediated via activation of NANC inhibitory pathways to the GI tract and requires an intact vagus nerve. Evidence suggests that, within the DVC, CRF has a dual role. In the NTS, CRF increases the probability of release of an excitatory neurotransmitter, most probably glutamate, however, the predominant role of CRF in the DVC is to directly excite DMV neurones by depolarization and a reduction in the amplitude of the AHP.
